APA (7th ed.) Citation

Lingyan, K., & Jun, M. (2025). Clinical and biochemical efficacy zoledronic acid and denosumab combination: Focus serum inflammatory factor level (serum ifcs), bone gla protein (bgp), and bone turnover markers b-collagen degradation product (b-ctx), and procollagen type 1 n-terminal propeptide (p1np). Society of Medical Biochemists of Serbia, Belgrade.

Chicago Style (17th ed.) Citation

Lingyan, Kong, and Ma Jun. Clinical and Biochemical Efficacy Zoledronic Acid and Denosumab Combination: Focus Serum Inflammatory Factor Level (serum Ifcs), Bone Gla Protein (bgp), and Bone Turnover Markers B-collagen Degradation Product (b-ctx), and Procollagen Type 1 N-terminal Propeptide (p1np). Society of Medical Biochemists of Serbia, Belgrade, 2025.

MLA (9th ed.) Citation

Lingyan, Kong, and Ma Jun. Clinical and Biochemical Efficacy Zoledronic Acid and Denosumab Combination: Focus Serum Inflammatory Factor Level (serum Ifcs), Bone Gla Protein (bgp), and Bone Turnover Markers B-collagen Degradation Product (b-ctx), and Procollagen Type 1 N-terminal Propeptide (p1np). Society of Medical Biochemists of Serbia, Belgrade, 2025.